Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third dose schedule of COVID-19 inactivated vaccine in adults
NCT05164731Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sars-cov-2 vaccine inactivated vero cell in coronavirus disease 2019 (COVID-19), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
sars-cov-2 vaccine inactivated vero cell
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05164731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164731.